Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anesiva Reports Positive Phase III Results For Zingo In Adults

This article was originally published in The Pink Sheet Daily

Executive Summary

Company plans to file for expanded indication in the first quarter of 2008.

You may also be interested in...



Anesiva Outlines Phase III Development For Pain Candidate Adlea

Two Phase III trials, for pain management in total knee replacement and bunionectomy surgeries, expected to begin in first half of 2008.

Anesiva CEO John P. McLaughlin: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

McLaughlin discusses Anesiva’s newly approved drug Zingo and the firm’s plan to partner the topical local anesthetic in the U.S. and ex-U.S.

Anesiva’s Fast-Acting Analgesic Zingo Clears FDA Ahead Of User Fee Date

The company is seeking a U.S. partner to aid in the launch of its first drug, CEO says.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel